AgingResearch.NewsJoin free

Vividion Therapeutics

CompanyUnited StatesFounded 2013

RORWikidata

Vividion Therapeutics develops one asset, in phase 2 (VVD-214 in advanced colorectal cancer). Mostly small molecule acting on wrn; based in the United States, founded in 2013.

1
Asset
Furthest stage
Phase 2
Raised
$464M
4
Trials
0
Signals

Pipeline

1

  • VVD-214

    Inhibits Werner helicase, disrupting DNA repair in susceptible cancer cells.

    Phase 2, Small molecule, wrn, advanced colorectal cancer

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials4
  • Funding rounds and grants7
  • Similar companies2

Papers

Intelligence